Skip to main content
Skip to primary sidebar

The Chandler Project

Home
About
News
Events
Contact

Blog

Primary Sidebar

The Chandler Project

The Chandler Project is a patient-focused organization that provides those affected by achondroplasia + other forms of dwarfism & skeletal dysplasia with the latest in pharmaceutical research and surgical advancements.
🦋 🦋 🦋

Achondroplasia Research News

Follow on Instagram

Posted @withregram • @draaronhuser Just finished training for #VOXZOGO administration with Abby, our genetics counselor, and the BioMarin team.

From the National Center for Biotechnology Information at @nlm_collections @nihgov –

Link in bio – From Beijing #Obstetrics and #Gynecology Hospital, Capital Medical University: Non-Invasive #Prenatal Detecting of #Achondroplasia In Earlier Stage of #Pregnancy By Droplet-Digital PCR

Posted @withregram • @paleyinstitute Mark your calendars for Friday, December 17th at 4:00 PM EST for Fridays with Feldman, with a special guest, Dr. Huser. Drs. Feldman and Huser will be discussing, "Achondroplasia, new BioMarin drug VOXZOGO (Vosoritide) approved by the FDA." Ask your questions in the comments below!

Recent Posts

BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates
European Commission Approves BioMarin’s VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Vosoritide in Europe: will payers cover BioMarin’s dwarfism drug?
BioMarin gears up for two ‘transformational’ launches, Voxzogo and Roctavian: CEO
Rarities With Anesthetic Implications: Lupus, Pemphigus, Achondroplasia

Categories

Achondroplasia
Ascendis
BioMarin
Health & Wellness
Hypochondroplasia
Limb Lengthening
Pfizer
QED
Skeletal Dysplasia
Therachon

Archives

Archives

Copyright © 2022 · The Chandler Project, Inc. · Tax ID: 83-1692863

search

type + hit enter